The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans

Carolina Herrera, Mackenzie L. Cottrell, John Prybylski, ..., José Alcami, Karl R. Malcolm, Robin J. Shattock

cherrer1@imperial.ac.uk

Highlights

- Tenofovir-maraviroc combinations show greater potency in NHP than in human tissue
- Opposite drug distribution in mucosal tissues was observed between both species
- Greater loss of viral replication fitness with RT mutations for SIV than for HIV-1
- Ex vivo tissue models are a bridge between NHP studies and human clinical trials

Herrera et al., iScience 25, 104409
June 17, 2022 © 2022 The Authors.
https://doi.org/10.1016/j.isci.2022.104409
The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans

Carolina Herrera,1,11,* Mackenzie L. Cottrell,2 John Prybyski,2,11 Angela D.M. Kashuba,2 Ronald S. Veazey,3 Javier García-Pérez,4 Natalia Olejniczak,1 Clare F. McCoy,5 Paul Ziprin,6 Nicola Richardson-Harman,7 José Alcami,4,8,9 Karl R. Malcolm,5 and Robin J. Shattock1

SUMMARY
Non-human primates (NHP) are widely used for the pre-clinical assessment of antiretrovirals (ARVs) for HIV treatment and prevention. However, the utility of these models is questionable given the differences in ARV pharmacology between humans and macaques. Here, we report a model based on ex vivo ARV exposure and the challenge of mucosal tissue explants to define pharmacological differences between NHPs and humans. For colorectal and cervicovaginal explants in both species, high concentrations of tenofovir (TFV) and maraviroc were predictive of anti-viral efficacy. However, their combinations resulted in increased inhibitory potency in NHP when compared to human explants. In NHPs, higher TFV concentrations were measured in colorectal versus cervicovaginal explants (p = 0.042). In humans, this relationship was inverted with lower levels in colorectal tissue (p = 0.027). TFV-resistance caused greater loss of viral fitness for HIV-1 than SIV. This, tissue explants provide an important bridge to refine and appropriately interpret NHP studies.

INTRODUCTION
Antiretroviral (ARV)-based pre-exposure prophylaxis (PrEP) is an important strategy in reducing HIV-1 transmission rates and remains an important global public health priority. Despite the use of various animal models, including humanized mice (Hatzioannou and Evans, 2012) and sheep (Holt et al., 2015) for pre-clinical development, NHPs remain the most relevant challenge model to assess the potential efficacy of ARV prevention. However, dose-efficacy discrepancies between NHP studies and clinical trials, and between dosing routes, have been described (Romano et al., 2013; Anton et al., 2000). The gap in knowledge regarding the concentration-effect relationship in both species highlights the need to develop models that will facilitate comparison between NHPs and humans, thereby increasing the predictive capacity of NHP studies.

Many ARVs being considered for oral or topical PrEP, including the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir (TFV), and the entry inhibitor (EI) maraviroc (MVC), are already used in highly active ARV treatment (HAART). For these drugs, a substantial amount of pharmacokinetic (PK) and pharmacodynamic (PD) data is available, including concentrations in blood plasma and genital secretions (Dickinson et al., 2010; Cohen et al., 2007). However, drug concentration measurements in blood plasma are not representative of mucosal tissue concentrations (Lederman et al., 2004; Trezza and Kashuba, 2014; Cohen et al., 2007; Brown et al., 2011; Dumond et al., 2007, 2009), and mucosal tissues are histologically and immunologically different from blood (Anton et al., 2000), affecting the expected correlation between concentration and efficacy at mucosal sites. In addition, drug accumulation is specific to each mucosal compartment, with differences between the intestinal and the female genital tract (Cohen et al., 2007; Louissaint et al., 2013; Patterson et al., 2011).

Assessment of concentration-efficacy correlations in mucosal tissues between species could help clarify discrepancies between human and NHPs data. However, this would require a significant number of NHPs for each candidate ARV and increase the complexity and size of clinical trials. Mucosal tissue explant
models are an important tool for pre-clinical screening of PrEP regimens (Herrera and Shattock, 2014) and are increasingly being used in early clinical trials (McGowan et al., 2015, Fox et al., 2016; Anton et al., 2012; Richardson-Harman et al., 2012, 2014). Through tissue-associated drug pharmacological measurement and ex vivo challenge, the present study sought to assess the potential use of ex vivo mucosal tissue explants as a bridging model between NHPs studies and human clinical trials of anti-HIV PrEP candidates. Parallel studies with TFV and MVC were performed with NHP and human mucosal tissue explants to establish comparisons in the PK/PD relationship between both species.

RESULTS

In vivo viral replication fitness is recapitulated in tissue explants

We first established the viral replication fitness of subtype B R5-tropic HIV-1 isolates SIVmac32H and RT-SHIV clones in human and Rhesus macaque mucosal tissue explants, respectively. All isolates infected colorectal and cervicovaginal explants (Figure 1) and, in both species, higher levels of viral replication were observed in colorectal explants compared with ecto-cervical and vaginal tissues. However, in some NHPs the peak of infection was observed at day 11 with a subsequent decrease in p27 levels.

ARV resistance is increasingly prevalent (Pennings, 2013; Snedecor et al., 2014) and can be associated with a decrease in viral replication capacity as observed for NRTI-resistant isolates. Hence, we generated a panel of NRTI-resistant clonal HIV-1 YU.2 and SIVmac32H isolates containing single point mutations in RT, K65R, and/or...
M184V (Figure S1) which have been well characterized in patients (Margot et al., 2006; White et al., 2002). When the study was conducted, L313T/I321V and V314T/I321V mutations were described as inducing resistance to MVC (Westby et al., 2007); however, when the mutations were introduced in HIV-1YU.2, no reduction of inhibitory potency was observed for MVC (Figure S1). We did not further evaluate these variants in the study. Mimicking the fitness loss observed in vivo, the three NRTI-resistant isolates showed reduced viral replication capacity in human explants compared to the wild-type clone (Figure 1B). However, in explants from some NHPs higher levels of viral replication were observed with SIVmac32H M184V (Figure S2). Hence, the loss of replication capacity was not consistent when the same mutations were introduced in an SIV backbone and tested in NHP explants compared to an HIV-1 mutant used in human explants.

Antiretroviral combinations are more potent in non-human primates than in human mucosal tissues

We evaluated the potency of TFV and MVC in mucosal tissue explants against challenge with the panel of HIV-1/SIV/SHIV isolates. TFV and MVC were applied topically, formulated alone or in combination in an aqueous hydroxyethylcellulose (HEC) gel; HEC gels are widely used for vaginal and rectal administration of drugs (Ciolacu et al., 2020). ARVs were applied 1 h before the challenge and removed 2 h post-challenge by washing in PBS. In NHP and human explants, greater potency was observed for TFV and MVC in colorectal tissue when compared to female genital tract tissue (Table 1) with median (IQR) fold decreased IC₅₀ values for matched isolates of 1.8 (1.7–2.1). Although increased inhibition was observed for all treatments when TFV and MVC were dosed in combination vs individually, synergy was not observed (median Ψ estimates from non-competitive joint inhibition interaction model ranged from 1.1 to 3.6; Table 1). Interestingly, higher Ψ values of 3.6 and 2.7 (possibly indicative of antagonism) were observed in both human and NHP cervical explants, respectively. As expected, the potency of TFV was reduced against the mutant isolates, with no impact on the potency of MVC (Table 1).

Pharmacology of tenofovir and maraviroc in non-human primates and human mucosal explants

Tissue concentrations of TFV and MVC and intracellular concentrations of the diphosphorylated active form of TFV (TFVdp) were measured following the 3 h ex vivo ARV exposure and viral challenge of explants. In

| Specie | Tissue | Isolate           | IC₅₀ (µM)¹ | Interaction Ψ |
|--------|--------|-------------------|------------|--------------|
|        |        | TFV               | MVC        |              |
| Human  | Cervical | HIV-1_BaL         | 41.35 ± 0.57 | 2.85 ± 0.49 | 3.6           |
|        |        | HIV-1_BaL         | 22.15 ± 1.39 | 1.26 ± 0.49 | 1.1           |
|        |        | HIV-1_YU2         | 28.86 ± 11.82 | 1.15 ± 0.84 | N.R.          |
|        |        | HIV-1_YU2 K65R    | 62.37 ± 15.80 | 2.77 ± 1.12 | N.R.          |
|        |        | HIV-1_YU2 M184V   | 37.85 ± 12.49 | 1.24 ± 1.88 | N.R.          |
|        |        | HIV-1_YU2 K65RM184V | 36.39 ± 3.83 | 1.43 ± 0.98 | N.R.          |
| NHP    | Cervical | SIVmac32H         | 52.65 ± 41.49 | 2.74 ± 1.18 | 2.7           |
|        |        | SIVmac32H K65RM184V | 81.30 ± 50.81 | 4.57 ± 2.92 | N.R.          |
|        | Vaginal | SIVmac32H         | 56.14 ± 62.94 | 3.32 ± 3.19 | 1.2           |
|        |        | SIVmac32H K65RM184V | 77.14 ± 31.54 | 3.31 ± 1.68 | 1.4           |
|        |        | RT-SHIV           | 52.15 ± 27.32 | 2.56 ± 1.59 | 1.5           |
|        |        | SIVmac32H         | 25.41 ± 5.35  | 1.96 ± 1.30 | 1.4           |
|        |        | SIVmac32H K65RM184V | 47.89 ± 24.89 | 1.98 ± 1.07 | 1.8           |
|        |        | RT-SHIV           | 29.96 ± 13.25 | 2.32 ± 0.78 | 1.7           |
|        |        | SIVmac32H K65R    | 46.55 ± 12.60 | 2.12 ± 0.89 | 1.6           |
|        |        | SIVmac32H M184V   | 40.20 ± 30.10 | 3.37 ± 1.21 | 1.4           |

¹Data are means (± SD) derived from three independent experiments performed in triplicate with human tissue and from independent experiments performed in duplicate with six macaques for wild-type isolates and at least three animals for resistant isolates. Median psi (Ψ) parameter where <1 indicates synergy, one additivity, and >1 antagonism.
human explants, average TFV exposure (AUC\textsubscript{3h-15d}) was significantly higher in ecto-cervical when compared to colorectal explants (fold change = 3.7, \(p = 0.002\); Figure 2, Table S1). By comparison, MVC exposure was similar between tissue types (fold change = 1.3, \(p = 0.655\)). In NHP explants, exposure for both ARVs trended higher in colorectal explants than in ecto-cervical (fold change = 2.5, \(p = 0.470\) for TFV and fold change = 3.8, \(p = 0.201\) for MVC) and vaginal tissues (fold change = 4.4, \(p = 0.373\) for TFV and fold change = 4.3, \(p = 0.209\) for MVC) without reaching statistical significance (Figure 3, Table S2). No significant differences were observed for these PK parameters between ecto-cervical and vaginal explants. Notably, when comparing the ARV concentrations measured in human and macaque tissues, \(C_{\text{max}}\) for TFV and MVC were significantly higher in human ecto-cervical explants than in macaque tissue (fold increase: 5.6, \(p = 0.003\) for TFV and 2.2, \(p = 0.032\) for MVC), and there was a trend to lower \(C_{\text{max}}\) values for both drugs in human colorectal explants than in macaque tissue (fold increase: 8.4, \(p = 0.221\) for TFV and 11.5, \(p = 0.240\) for MVC). With the harvesting schedule of the assay, TFVdp was neither detected in humans nor in NHP ecto-cervical explants. However, this analyte was found in NHP vaginal tissue explants at \(t_0\), and the \(C_{\text{max}}\) was lower than in colorectal explants (fold increase: 1.6, \(p = 0.020\)). No significant differences in TFVdp concentrations were found in colorectal explants between NHP and humans.

When comparing the different ex vivo dosing concentrations, significantly higher PK parameters were measured in both human tissues after exposure to high concentration gels with TFV (\(p < 0.0001\)) (AUC\textsubscript{3h-15d} fold increase: 6.6 in ecto-cervical explants, 2.9 in colorectal tissue) and with MVC (AUC\textsubscript{3h-15d}

---

**Figure 2. Concentrations of TFV and MVC in human mucosal tissue explants**  
Human (A, C, and E) colorectal and (B, D, and F) ecto-cervical tissue explants were incubated for 3 h with TFV at 70 \(\mu\text{M}\) (●) or 7 \(\mu\text{M}\) (○), MVC at 3.8 \(\mu\text{M}\) (▲) or 0.38 \(\mu\text{M}\) (△), TFV 70 \(\mu\text{M}\) = MVC 3.8 \(\mu\text{M}\) (● and ▲, respectively) or TFV 7 \(\mu\text{M}\) = MVC 0.38 \(\mu\text{M}\) (○ and △, respectively). Explants were harvested at different time points and concentrations of TFV, TFVdp or MVC measured. Data are median (IQR) derived from three independent experiments performed in duplicate.
fold increase: 4.3 (p = 0.0002) in ecto-cervical explants; 5.4 (p < 0.0001) in colorectal tissue). In macaque explants, this high correlation between ARV concentration exposure-high tissue drug concentration was also observed; however, statistical significance was only reached for both drugs in vaginal explants (AUC3h-15d 2.1-fold increase for TFV, p = 0.006; 3.8-fold increase for MVC, p < 0.0001), and for MVC in ecto-cervical explants (AUC3h-15d 14.1-fold increase, p < 0.033). In human colorectal explants, high TFV PK values tended to correlate with greater concentrations of TFVdp. This correlation was neither observed in NHP colorectal nor in vaginal explants.

No effect was observed on PK parameters of each drug when human explants were treated with the ARV-combination. However, in NHPs explants, combining the two ARVs resulted in an increase of these parameters for both drugs reaching statistical significance only for TFV in ecto-cervical explants (AUC3h-15d 2.2-fold increase, p = 0.036) (Figure 3, Table S2).

The p24 and p27 concentrations at different time points during the 15 days of culture allowed us to calculate p24 or p27 AUCr between days 3 and 15 of culture (p24/p27 AUC3,15) (Table S3). In general, and as expected following explant dosing with ARVs, lower p24/p27 AUC3,15 values were measured in ARV-dosed explant cultures than in untreated samples. On average, a further decrease was observed with combinations in comparison to each individual drug. For each ARV, tested alone and in combination, the lowest p24/p27 AUC3,15 were obtained with the higher concentration gels as greater levels of inhibition were reached. Specifically, the decrease of p24 AUC3,15 values between the drugs used in combination and
tested alone reached statistical significance for TFV against HIV-1YU2 (p = 0.049 at high concentration) and resistant HIV-1YU2 isolates (p = 0.046 at high concentration against HIV-1YU2 K65R, p = 0.012 at high concentration against HIV-1YU2 M184V, p = 0.020 at low concentration against HIV-1YU2 K65RM184V) in colorectal tissue. Further reductions were measured for the two ARVs alone and in combination with the high compared to the low concentration gel with statistical significance in colorectal explants against SIVmac32H (p = 0.005 at high concentration, and p = 0.003 at low concentration). When greater anti-viral activity was obtained with an increase of the dosing concentration, lower p27 AUC3-15 values were also calculated with significant differences for the two drugs alone and/or in combination in colorectal explants against SIVmac32H K65RM184V (p = 0.049 for TFV-MVC).

**Ex vivo drug concentration and infectivity inversely correlate in explants**

Negative correlations between explant drug concentration and HIV p24 or SIV p27 concentrations were found in human and NHP explants (Figure 4), demonstrating the relationship between increased tissue drug concentrations and lower levels of infection in the ex vivo model. Notably, however, in human explants, we observed greater negative values for the slope of the linear correlation than in NHPs (Figure 4G).

The PK-PD linear correlation for TFV was statistically significant in all human and NHP tissue types (Figure 4G). Hence, we decided to further investigate these correlations by assessing if a non-linear correlation would be a better fit. Analysis revealed that a non-linear fit was possible (Table S4). However, statistical significance was only reached in ecto-cervical human explants and in vaginal NHP explants.

**DISCUSSION**

Here, we have demonstrated discrepancies in ARV exposure and potency between species (human vs NHP) and tissue type (female genital vs colorectal) in the mucosal tissue explant model. The order of potency in tissue explants with TFV and MVC was the same as that described in the literature in cellular models (Herrera et al., 2016) and in vivo in NHPs (Dobard et al., 2015), and it was maintained in all tissue models and in both species (Table 1). Furthermore, and as reported previously in NHPs (Dobard et al., 2015), when the drugs were tested in combination in the explant model there was an increase in inhibitory activity for both drugs in NHPs and humans. However, increased inhibition tended to be higher in NHP vs human explants and lower in cervical vs vaginal and colorectal explants and did not meet our definition of synergy within any explant condition. These differences could be related to lower level of viral replication in cervicovaginal tissue explants (Figures 1A and 2), which mimics the lower in vivo susceptibility of female genital tract to HIV infection compared to colorectum. The relatively high vulnerability of the colorectal tract to HIV-1 transmission is likely owing to histological and immunological differences between intestinal and genital mucosa. Colorectal mucosa has a single-cell columnar epithelium in contrast to the pluri-stratified squamous epithelium of the lower female genital tract. Moreover, intestinal lamina propria contains an abundance of highly activated target cells for HIV infection, can transfer infectious virus to the underlying lymphoid tissue and is the major site of viral replication and CD4 T cell depletion during acute infection (Anton et al., 2000; Lapenta et al., 1999; Poles et al., 2001). The loss of viral fitness described in vivo for NRTI-resistant isolates (McColl et al., 2004; Lloyd et al., 2016) was also mimicked in tissue explants (Figures 1B and 2). However, this model revealed differences in the viral replication capacity with a more pronounced loss for HIV-1 mutants tested in human explants than for resistant SIV isolates in NHP explants. The viral replication differences observed between humans and NHP could be linked to immunological specificities. Different immune cell type frequencies have been described for both species in blood (Bjornson-Hooper et al., 2019), which could affect the mucosal immune content. Another factor that has been described to affect HIV susceptibility and ARV PK/PD in mucosal compartments is the microbiota (Abdool Karim et al., 2019). Microbial communities have been described to differ between humans and NHPs (Chen et al., 2018). However, in our model, the sustained use of antibiotic and antifungal cocktail before and after dosing and challenge annul this factor.
The activity of MVC depends on its binding to CCR5; despite differences in the kinetics of dissociation described between rhesus and human CCR5 (Napier et al., 2005), NHP studies (Massud et al., 2013) and clinical trials (Coll et al., 2015; Fox et al., 2016; McGowan et al., 2019; McGowan et al., 2022; Sekabira et al., 2021) have shown limited protective potency even in the presence of MVC at levels above the minimum effective concentration. Pre-clinical (Herrera et al., 2016; Fletcher et al., 2016) and clinical (McGowan et al., 2019; Sekabira et al., 2021) studies using the ex vivo challenge model have shown that frequent repeat dosing or combination with other ARVs increases the inhibitory activity of MVC.

Figure 4. Ex vivo drug concentration and infectivity inversely correlate in explants
Linear correlations in solid lines are shown for C_{max} values of (A and D) TFV at day 0, (B and E) TFVdp found at day 3 and (C and F) MVC at day 0 correlated with p24 (A, B, and C) and p27 (D, E, and F) concentrations measured at day 15, after ex vivo exposure of tissue explants to gels containing high or low concentrations of drug alone or in combination, and challenge with HIV-1BaL. (G) Correlations were assessed using a Pearson correlation test. N/D: not detectable for tissues where all observations were below the limits of quantification (BLQ). The data are derived from at least three independent experiments (n = 3 for human tissues, n = 6 for NHP colorectal and vaginal explants and n = 3 for NHP ecto-cervical tissue) performed in duplicate.

The activity of MVC depends on its binding to CCR5; despite differences in the kinetics of dissociation described between rhesus and human CCR5 (Napier et al., 2005), NHP studies (Massud et al., 2013) and clinical trials (Coll et al., 2015; Fox et al., 2016; McGowan et al., 2019; McGowan et al., 2022; Sekabira et al., 2021) have shown limited protective potency even in the presence of MVC at levels above the minimum effective concentration. Pre-clinical (Herrera et al., 2016; Fletcher et al., 2016) and clinical (McGowan et al., 2019; Sekabira et al., 2021) studies using the ex vivo challenge model have shown that frequent repeat dosing or combination with other ARVs increases the inhibitory activity of MVC.
We assessed the combinatorial activity (synergy/additivity/antagonism) of TFV and MVC using a previously published non-competitive joint inhibition model (Chakraborty and Jusko, 2002). Although we saw increased inhibitory activity by our combination treatment, we did not observe a synergistic interaction. Given that previous studies with cell culture models have demonstrated synergy between TFV and MVC (Srinivas et al., 2020), this finding may be specific to explant systems and could be attributable to early physiologic changes that have been described in cultured tissues that can influence ARV potencies such as decreased CCR5 expression and deoxynucleotide concentrations (Nicol et al., 2015).

Differences in TFV and MVC exposure were also observed in our ex vivo tissue explant model. For both ARVs, exposure (i.e., AUC$_{24-156}$) was higher in cervicovaginal and colorectal NHP explants when compared to human tissue (Tables S1 and S2). Importantly, lower TFV exposure was observed in NHP ecto-cervical than in colorectal explants and the opposite distribution was measured in human explants. Higher intracellular TFVdp concentrations have been found in rectal tissue than in vaginal tissue of pigtail macaque (Radzio et al., 2012) similar to our results with mucosal explants from rhesus macaque. These results further correlate with an NHP study where the drug concentration measured in vaginal fluid after vaginal dosing was lower than in rectal fluid following rectal dosing (Nuttall et al., 2012). Thus, in vivo NHP studies might overestimate the amount of drug required to obtain equivalent colorectal dosage in humans and underestimate the amount required for ecto-cervical tissue. These pharmacological differences are linked to multiple factors, in addition to microbiome, such as drug transporters, whose expression patterns are not only tissue-dependent but also distinct between NHPs and humans. Lower levels of ARV efflux transporters have been described in the NHP female genital tract compared to humans (Hijazi et al., 2020) which explain the distinct ARV retention levels measured in our study. Furthermore, and in parallel to our results, species-dependent drug distribution has also been observed in the gut following oral dosing of macaques and humans with several ARVs including TFV and MVC among others (Akabane et al., 2010; Thompson et al., 2019). Another important factor in the pharmacology of TFV is the activity of the kinases involved in the intracellular phosphorylation of TFV resulting in the active diphosphorylated metabolite, TFVdp. This phosphorylation occurs in two steps, adenylate kinase 2 (AK2) phosphorlates TFV to TFV-monophosphorylated (mp) in female genital tract and colorectal tissue; while phosphorylation of TFVmp to TFVdp in colorectal tissue is catalyzed by creatine kinase, muscle (CKM), and by pyruvate kinase liver and red blood cell (PKM) and pyruvate kinase liver and red blood cell (PKLR) in vaginal tissue (Lade et al., 2015). Furthermore, AK2 has a 100% between humans and rhesus macaques (https://www.uniprot.org/); however, to our knowledge, no study has assessed if the 90% homology between these two species for the other three kinases affects the efficacy of TFV metabolism. These factors could impact the predictive power of animal models and should be further studied in comparative tissue explant studies.

However, the lack of significant differences in PK parameters for TFV and MVC between ecto-cervical and vaginal explants from NHPs (Table S2) is in accordance with a study where after topical vaginal application of TFV in women no differences were observed in drug concentrations between proximal and distal areas of the female genital tract (Schwartz et al., 2011). A recent publication by Nicol et al. showed that peak expression of the intracellular active metabolite TFVdp is detected between 24 and 48 h after TFV dosing (Nicol et al., 2015). Our harvest schedule on days 0, 3, 7, 11, and 15 of explant culture was defined before that publication, resulting in the measurement of tissue TFVdp during its decay phase. Nevertheless, this schedule exhibited greater persistence of metabolite in colorectal explants, where the metabolite was still detected up to 3 days post-dose vs just 3 h post-dose in vaginal tissue. This could be owing to the differential expression of kinases and nucleosidases responsible for adding and removing phosphate groups on nucleotide analogs (Hu et al., 2014). The explant model also recapitulated the higher concentrations of TFVdp in colorectal tissue compared to cervicovaginal mucosa measured in various clinical trials (Karim et al., 2011).

Macques remain the main challenge model for HIV/AIDS; however, pre-clinical data for the prioritization of ARVs and vaccines need to be supplemented with the evaluation of other factors than protection against in vivo challenge of macaques, to predict efficacy in clinical trials. Refinement of NHP models and further characterization in tissue explant models of key factors affecting the pharmacology of HIV prevention strategies are needed. Using only human tissue explants to prioritize candidate ARVs would involve financial, time, and ethical constraints linked to the recruitment of a large number of participants. Ex vivo challenge of tissue explants would allow conversion between the tissue drug concentrations needed to obtain protection in NHPs with the concentration required for efficacy in human tissue. Hence, the tissue explant model may provide an important bridge between NHP PrEP studies and human clinical trials, refining the NHP model to enhance the predictive utility of NHPs and reducing the risk of late-stage failure in clinical trials.
Limitations of the study
The unavailability of human vaginal tissue in this study represents a limitation to establish the potential effect of the intrinsic variability within the human cervicovaginal compartment.

The main limitation of this study is the relatively small sample size, with no opportunity to evaluate other drug concentrations, ARVs, and viral isolates in specimens such as ecto-cervical tissue. The choice of RT-SHIV, instead of an Env-SHIV, was taken on the basis that results obtained with RT-SHIV could potentially serve for the design of combination-based prevention strategies including TFV or MVC and non-NRTI ARVs, which are not active against all SIV isolates (Ambrose et al., 2004; Isaka et al., 2000). Although the results obtained in this study might not be representative of the broad range of ARVs currently in the HIV prevention pipeline, the evaluation of two ARVs with different mechanisms of action and cellular transport/efflux give sufficient evidence to highlight the need to adapt the pre-clinical criteria of the selection of candidate ARVs to each drug and to its activity in different mucosal tissues from humans or NHPs.

The explant model has limitations, including (i) progressive loss of architecture despite the maintenance of CD4:CD8 T cell ratios and sufficient viability to sustain viral replication for more than 10 days (Fletcher et al., 2006); (ii) paucity of data regarding the preservation of immune competence (Grivel and Margolis, 2009); (iii) limitation to demonstrate sterilizing protection; and (iv) inability to metabolize certain prodrugs such as tenofovir disoproxil fumarate which is the formulated version of TFV for oral administration.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- METHOD DETAILS
  - Animal welfare
  - Human tissues
  - Reagents and plasmids
  - Cell, tissue explants and virus culture conditions
  - Infectivity and inhibition assays in tissue explants
  - Drug concentrations in tissue explants
  - Pharmacological data analysis
  - Statistics
  - Study approval

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2022.104409.

ACKNOWLEDGMENTS
We thank Naomi Armanasco and Abbey Evans for human tissue collection support; the Department of Surgery and Cancer and the Department of Obstetrics and Gynecology at St. Mary’s Hospital, Imperial College for their assistance in obtaining human tissue; and Terri A. Rasmussen, Meagan A. Watkins, Megan B. Gardner and the veterinary, surgical and administrative teams at the TNPRC. We are grateful to Jim Turpin (NIH), Prof. Graham Taylor, and Prof. Martin Cranage for useful discussion. This work was supported by an NIH R21 award AI094515 and by the European Commission’s seventh Framework “Combined Highly Active Retroviral Microbicides” (CHAARM) (242135). This work was partially supported by project PI19CIII/00004 and the Spanish AIDS Research Network (RIS) funded by Instituto de Salud Carlos III and co-funded by European Development Fund (ERDF) “A way to build Europe” (project RD16CIII/0002/0001).

AUTHOR CONTRIBUTIONS
Conceptualization: C.H. and R.J.S.; methodology: C.H., A.D.M.K., R.S.V, and K.R.M.; investigation: C.H., J.G.P., N.O., and R.W.; resources: C.F.M., P.Z., J.A., and K.R.M; analysis: C.H., M.L.C., J.P., R.W., and
N.R.H; writing-original draft preparation, C.H.; writing-review and editing by all authors; visualization: C.H., M.L.C., and J.P.; supervision: C.H.; project administration: C.H; funding acquisition: C.H. All authors have read and agreed to the published version of the article.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: November 11, 2021
Revised: May 11, 2022
Published: June 17, 2022

REFERENCES

Abdool Karim, S.S., Baxter, C., Passmore, J. -A.S., Mckinnon, L.R., and Williams, B.L. (2019). The role of the genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women. J. Int. AIDS Soc. 22, e25300. https://doi.org/10.1002/jia2.25300.

Akabane, T., Tabata, K., Kadono, K., Sakuda, S., Terashita, S., and Teramura, T. (2010). A comparison of pharmacokinetics between humans and monkeys. Drug Metab. Dispos. 38, 308–316. https://doi.org/10.1124/dmd.109.020829.

Ambrose, Z., Boltz, V., Palmer, S., Coffin, J.M., Hughes, S.H., and Kewalramani, V.N. (2004). In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J. Virol. 78, 13553–13561. https://doi.org/10.1128/JVI.24.13553-13561.2004.

Anton, P.A., Cranston, R.D., Kashuba, A., Hendrix, C.W., Bumpus, N.N., Richardson-Harman, N., Elliott, J., Janocco, L., Kanhukova, E., Dennis, R., et al. (2012). RMP-02/MTN-006: a phase 1 rectal pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. J. Antimicrob. Chemother. 67, 591–601. https://doi.org/10.1093/infdis/jir373.

Coll, J., Molto, J., Boix, J., Gomez-Mora, E., Else, L., Garcia, E., Paredes, R., Ouchi, D., Carrillo, A., Escrig, R., et al. (2015). Single oral dose of maraviroc does not prevent ex-vivo HIV-1 infection of rectal mucosa in HIV-1 negative human volunteers. AIDS. 29, 2149–2154. https://doi.org/10.1097/QAD.0000000000001108.

Derderyan, C.A., Decker, J.M., Sfakianos, J.N., Wu, X., O’Brien, W.A., Rainer, L., Kappes, J.C., Shaw, G.M., and Hunter, E. (2000). Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74, 8358–8367. https://doi.org/10.1128/JVI.74.18.8358-8367.2000.

Dickinson, L., Khoo, S., and Back, D. (2010). Pharmacokinetics and drug-drug interactions of antiretroviral drugs. Antivir. Res. 85, 176–189. https://doi.org/10.1016/j.antivir.2009.07.017.

Dobard, C.W., Taylor, A., Sharma, S., Anderson, P.L., Bushman, R.L., Chuong, D., Pau, C.P., Hansol, D., Wang, L., Garcia-Lemma, J.G., et al. (2015). Protection against rectal chimeric simian/human immunodeficiency virus transmission in macaques by rectal-specific gel formulations of maraviroc and tenofovir. J. Infect. Dis. 212, 1988–1995. https://doi.org/10.1093/infdis/jiv334.

DuBridge, R.B., Tang, P., Hsia, H.C., Leong, P.M., Miller, J.H., and Calos, M.P. (1987). Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7, 379–387. https://doi.org/10.1128/mcb.7.1.379.

Dumond, J.B., Patterson, K.B., Peche, A.L., Werner, R.E., Andrews, E., Damle, B., Tressler, R., Worsley, J., and Kashuba, A.D.M. (2007). Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J. Acquir. Immune Defic. Syndr. 51, 546–553. https://doi.org/10.1097/QAI.0b013e31804e6c5c.

Dumond, J.B., Yeh, R.F., Patterson, K.B., Corbett, A.H., Jung, B.H., Rezk, N.L., Bridges, A.S., Stewart, P.W., Cohen, M.S., and Kashuba, A.D.M. (2007). Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 21, 1899–1907. https://doi.org/10.1097/QAD.0b013e328237088c.

Fletcher, P., Herrera, C., Armanasco, N., Nuttall, J., and Shattock, R.J. (2016). Short communication: limited anti-HIV-1 activity of maraviroc in mucosal tissues. AIDS Res. Hum. Retroviruses 32, 334–338. https://doi.org/10.1016/j.aids.2015.03.015.

Fletcher, P.S., Elliott, J., Grivel, J.C., Margolis, L., Anton, P., McGowan, I., and Shattock, R.J. (2006). Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 20, 1237–1245. https://doi.org/10.1097/01.aids.0000223230.96134.80.

Fox, J., Tiraboschi, J.M., Herrera, C., Else, L., Egan, D., Dickinson, L., Jackson, A., Olejniczak, N., Back, D., Khoo, S., et al. (2016). Brief report: pharmacokinetic/pharmacodynamic investigation of single-dose oral maraviroc in the context of HIV-1 pre-exposure prophylaxis. J. Acquir. Immune Defic. Syndr. 73, 252–257. https://doi.org/10.1097/QAI.0000000000001108.

Garcia-Perez, J., Perez-Olmeda, M., Sanchez-Palomino, S., Perez-Romo, P., and Alcamí, J. (2008). A new strategy based on recombinant viruses for assessing the topical capacity of HIV-1. HIV Med. 9, 160–171. https://doi.org/10.1111/j.1468-1293.2007.00540.x.

Gartner, S., Markovits, P., Markovits, D.M., Kaplan, M.H., Gallo, R.C., and Popovic, M. (1986). The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233, 215–219. https://doi.org/10.1126/science.3014648.
helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. U S A 90, 8392–8396. https://doi.org/10.1073/pnas.90.18.8392.

Pennings, P. S. (2013). HIV drug resistance: problems and perspectives. Infect. Dis. Rep. 5, e5. https://doi.org/10.4081/idr.2013.s1.e5.

Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B., and Kabat, D. (1998). Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage-tropic isolates of human immunodeficiency virus type 1. J. Virol. 72, 2855–2864. https://doi.org/10.1128/jvi.72.4.2855-2864.1998.

Poles, M. A., Elliott, J., Taing, P., Anton, P. A., and Chen, I. S. (2001). A preponderance of CCR5(+)/CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J. Virol. 75, 8390–8399. https://doi.org/10.1128/jvi.75.18.8390-8399.2001.

Radzio, J., Aung, W., Holder, A., Martin, A., Sweeney, E., Mitchell, J., Badman, S., Pau, C. P., Heneine, W., and Garcia-Lerma, J. G. (2012). Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS One 7, e50632. https://doi.org/10.1371/journal.pone.0050632.

Richardson-Harman, N., Hendrix, C. W., Bumpus, N. N., Mauck, C., Cranston, R. D., Yang, K., Elliott, J., Tanner, K., Mgcogwan, I., Kashuba, A., and Anton, P. A. (2014). Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study. PLoS One 9, e111507. https://doi.org/10.1371/journal.pone.0111507.

Richardson-Harman, N., Mauck, C., Mgcogwan, I., and Anton, P. (2012). Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study. AIDS Res. Hum. Retroviruses 28, 1422–1433. https://doi.org/10.1089/aid.2012.0073.

Romano, J., Kashuba, A., Becker, S., Cummins, J., Turpin, J., and Veroneze, F. (2013). Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention. AIDS Res. Hum. Retroviruses 29, 1418–1427. https://doi.org/10.1089/aid.2013.0172.

Rud, E. W., Cranage, M., Yon, J., Qurik, J., Ogilvie, L., Cook, N., Webster, S., Dennis, M., and Clarke, B. E. (1994). Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J. Gen. Virol. 75, 529–543. https://doi.org/10.1099/0022-1317-75-3-529.

Schwartz, J. L., Rountree, W., Kashuba, A. D. M., Brache, V., Creinin, M. D., Poindexter, A., and Kearney, B. P. (2011). A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 6, e25974. https://doi.org/10.1371/journal.pone.0025974.

Sekabira, R., Mgcogwan, I., Yuhas, K., Brand, R. M., Marzinke, M. A., Manabe, Y. C., Frank, I., Eron, J., Landovitz, R. J., Anton, P., et al. (2021). Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. AIDS 35, 1585–1599. https://doi.org/10.1097/QAD.0000000000002907.

Snedecor, S. J., Sudharshan, L., Nedrow, K., Bhaneagaonkar, A., Simpson, K. N., Haider, S., Chambers, R., Craig, C., and Stephens, J. (2014). Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. AIDS Res. Hum. Retroviruses 30, 753–768. https://doi.org/10.1089/aid.2013.0262.

Soderberg, K., Denekamp, L., Nikiforov, S., Sautter, K., Desrosiers, R. C., and Alexander, L. (2002). A nucleotide substitution in the rNA(lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 76, 5803–5806. https://doi.org/10.1128/jvi.76.11.5803-5806.2002.

Srinivas, N., Cottrell, M., Maffuid, K., Prince, H. A., Nelson, J. A. E., White, N., Sykes, C., Dellon, E. S., Madanick, R. D., Shaheen, N. J., et al. (2020). Translational approach to predicting the efficacy of maraviroc-based regimens as HIV preexposure prophylaxis. Antimicrob. Agents Chemother. 64, e01729-19. https://doi.org/10.1128/AAC.01729-19.

Thompson, C. G., Rosen, E. P., Prince, H. M. A., White, N., Sykes, C., De La Cruz, G., Mathews, M., Deleage, C., Estes, J. D., Charlins, P., et al. (2019). Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species. Sci. Transl. Med. 11, eaap9758. https://doi.org/10.1126/scitranslmed.aap8758.

Trezza, C. R., and Kashuba, A. D. M. (2014). Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention. Clin. Pharmacokinet. 53, 611–624. https://doi.org/10.1007/s40262-014-0148-z.

US DHHS, FDA, CDER (2001). Guidance for Industry: Bioanalytical Method Validation (US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine).

Veselinovic, M., Yang, K. H., Leecureux, J., Sykes, C., Remling-Muder, L., Kashuba, A. D. M., and Akkina, R. (2014). HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model. Virology 464–465, 253–263. https://doi.org/10.1016/j.viro.2014.07.008.

Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., and Kappes, J. C. (2002). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896–1905. https://doi.org/10.1128/aac.46.11.1896-1905.2002.

Westby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mosley, M., Stockdale, M., Dorr, P., Ciaramella, G., and Perros, M. (2007). Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCRI antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81, 2359–2371. https://doi.org/10.1128/jvi.0006-06.

White, K. L., Margot, N. A., Win, T., Petropoulos, C. J., Miller, M. D., and Naeger, L. K. (2002). Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 46, 3437–3446. https://doi.org/10.1128/aac.46.11.3437-3446.2002.
## KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Bacterial and virus strains** | | |
| HIV-1 BaL | NIH AIDS reagent program | ARP-510 |
| RT-SHIV | Soderberg, K. et al., 2002 | N/A |
| **Biological samples** | | |
| Human colorectal fresh tissue | Imperial College Healthcare Tissue Bank | https://www.imperial.ac.uk/imperial-college-healthcare-tissue-bank/ |
| Human ecto-cervical fresh tissue | Imperial College Healthcare Tissue Bank | https://www.imperial.ac.uk/imperial-college-healthcare-tissue-bank/ |
| Human peripheral blood mononuclear cells | NHS Blood and Transplant | NC24 Leucocyte cone |
| **Chemicals, peptides, and recombinant proteins** | | |
| Hydroxyethylcellulose (HEC) (Natrosol™ 250 HX pharm) | Ashland / Aqualon | N/A |
| Maraviroc free base (UK-427857, PF-3419979) | Pfizer Ltd | Lot 0008 |
| Maraviroc | NIH AIDS reagent program | ARP-11580 |
| Tenofovir (PMPA, TFV, GS-1278) | CONRAD | N/A |
| Tenofovir | NIH AIDS reagent program | ARP-10199 |
| Emtricitabine (FTC) | NIH AIDS reagent program | ARP-10071 |
| **Critical commercial assays** | | |
| HIV-1 p24 ELISA | AIDS Vaccine Program, National Cancer Institute | N/A |
| HIV-1 p24 Antigen ELISA, RETROtek, Zeptometrix | Gentaur | 0801200 |
| SIV p27 Antigen ELISA, RETROtek, Zeptometrix | Gentaur | 0801201 |
| QuickChange Lightning Site-Directed Mutagenesis Kit | Agilent | 210514 |
| Lipofectamine 2000 | Life Technologies | 11668019 |
| Luciferase assay system | Promega | E4530 |
| Precellys® hard tissue reinforced metal beads kit (MK28-R) | Cayman Chemical | 16858 |
| **Experimental models: Cell lines** | | |
| TZM-bl cells | NIH AIDS reagent program | ARP-8129 |
| HEK 293T cells | ATCC | CRL-3216 |
| C8166 cells | NIBSC-CFAR | ARP013 |
| **Experimental models: Organisms/strains** | | |
| Rhesus macaque (Macaca mulatta) | Tulane National Primate Research Center | N/A |
| **Oligonucleotides** | | |
| Primer pYU.2-K65R-up: 5’-CTCCAGTATTTCGTGGCATAAAGAGAAAAGACAGTGTTCAAATGGAG-3’ | This paper | N/A |
| Primer pYU.2-K65R-down: 5’-CTCCACATTAGTACTCTTTTCTTTTATGGCAAAATACTGGGAG-3’ | This paper | N/A |
| Primer pYU.2-M184V-up: 5’-CCAGACCTAGTATGCTGTTATGCGTTGACAGTTGCTGTGG-3’ | This paper | N/A |
| Primer pYU.2-M184V-down: 5’-CTTCGTACATGATAAATTGGTACTGTGGTACATGATTG-3’ | This paper | N/A |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Carolina Herrera (cherrer1@imperial.ac.uk).

Materials availability
Plasmids generated in this study can be access upon request to the lead contact.

Data and code availability
- All data reported in this paper will be shared by the lead contact upon request.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
- No code was generated for this study.

METHOD DETAILS

Animal welfare
Six female Rhesus macaques (Macaca mulatta) of different ages (CF27: 13 years, FH12: 8 years, EM14: 9 years, V538: 16 years, FM15: 11 years, GI69: 6 years) were included in the study. Animals were not treated with Depo-Provera. Macaques were humanely euthanized with ketamine hydrochloride (10 mg/kg) and tiletamine / zolazepan (Telazol, 8 mg/kg) in accordance with the American Veterinary Medical Association Guidelines on Euthanasia, 2013.

Continued

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Primer pJ5-K65R-up: 5'-CACCCCCACATTTGCTAT AAAGAGAAAGATAGAACAATAATGGAG-3' | This paper | N/A |
| Primer pJ5-K65R-down: 5'-CTCCATTTGCTTTATTC TTTTCTTCTTATGAAATGTGGGCGT-3' | This paper | N/A |
| Primer pJ5-M184V-up: 5'-GATGTGACCCCTTAGCC AGTATGAGATGACATCTTAATAGCTAGTG-3' | This paper | N/A |
| Primer pJ5-M184V-down: 5'-CACTACATAGAACAAATGGAGTCACATC-3' | This paper | N/A |

Recombinant DNA
- pHIV-1 YU2: NIBSC-CFAR 100 840
- pHIV-1 YU2 K65R: This paper N/A
- pHIV-1 YU2 M184V: This paper N/A
- pHIV-1 YU2 K65R M184V: This paper N/A
- pJS del T-KS-(SIVmac32H): NIBSC-CFAR ARP229
- pSIVmac32H K65R: This paper N/A
- pSIVmac32H M184V: This paper N/A
- pSIVmac32H K65R M184V: This paper N/A

Software and algorithms
- GraphPad Prism (v.8): GraphPad Software, Inc. https://www.graphpad.com/
- SAS v9.5: SAS Institute Inc. https://www.sas.com
- R (v. 3.6.1): R Code Team and R Foundation for Statistical Analysis https://www.r-project.org/
- AB Sciex Analyst Chromatography Software (v. 1.6.2): Sciex https://sciex.com
Human tissues
Cervical tissue was obtained from adult pre-menopausal patients undergoing planned therapeutic hysterectomies with nonmalignant pathology or posterior and anterior vaginal repair surgery at St. Mary’s Hospital, Imperial College of London, United Kingdom. Colorectal tissue was obtained from patients undergoing rectocele repair and colectomy from colorectal cancer at St. Mary’s Hospital (London, United Kingdom). Only healthy tissue obtained at 10 to 15 cm away from any tumor was employed.

Reagents and plasmids
Aqueous HEC gels containing TFV (0.1 and 1% w/w), MVC (0.01 and 0.1% w/w), and two TFV + MVC combination gels (0.1 + 0.01% w/w, and 1 + 0.1% w/w) were manufactured as described previously (Malcolm et al., 2013).

HIV-1Bal (Gartner et al., 1986) was provided by the NIH AIDS Research & Reference Reagent Program (http://www.aidsreagent.org/). RT-SHIV (Soderberg et al., 2002) was kindly donated by Dr. Stahl-Hennig (DPZ, Germany). Full-length, replication and infection-competent proviral HIV-1YU.2 clone, pYU.2 (Li et al., 1992), and proviral SIVmac32H, pJS (Rud et al., 1994) were provided by the Center for AIDS Reagents (http://www.nibsc.org/). Infectious HIV-1 and SIV clones with K65R and/orM184V mutations were constructed as previously described (Garcia-Perez et al., 2008). Briefly, site-directed mutations were introduced by PCR in pYU-2 and pJS clones using the QuickChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) and the mutagenic primers following manufacturer instructions. Clones were sequenced to verify the mutations had been inserted.

Cell, tissue explants and virus culture conditions
All cell and tissue explant cultures were maintained at 37°C in an atmosphere containing 5% CO2. TZM-bl cells (Wei et al., 2002; Derdeyn et al., 2000; Platt et al., 1998) and human epithelial kidney (HEK) 293T cells (Pear et al., 1993, DuBridge et al., 1987) were grown in Dulbecco’s Minimal Essential Medium (DMEM) (Sigma-Aldrich, Inc., St. Louis, MO) and C8166 cells in RPMI 1640 medium (Sigma-Aldrich), both containing 10% fetal calf serum, 2 mM L-glutamine and antibiotics (100 U of penicillin/ml, 100 μg of streptomycin /ml, and for HEK 293T cells, 0.5 mg/ml of the neomycin analog G-418). Both cell lines were tested for mycoplasma contamination and confirmed mycoplasma-free.

Mucosal tissue specimens were transported to the laboratory and processed less than 1 h after resection. Upon arrival in the laboratory, resected tissue was cut into 2–3 mm3 explants comprising epithelial and stromal layers for ecto-cervical and vaginal tissue, or epithelium and muscularis mucosae for colorectal tissue, as described previously (Herrera et al., 2009; Hu et al., 2004). Tissue explants were maintained with DMEM containing 10% fetal calf serum, 2 mM L-glutamine and antibiotics (100 U of penicillin/ml, 100 μg of streptomycin /ml, 80 μg of gentamicin /ml).

Recombinant vectors and SIVmac32H were transfected in HEK293T cells with Lipofectamine 2000 following manufacturer’s instructions (Life Technologies, Carlsbad, CA). The laboratory-adapted isolate HIV-1Bal was passaged for 11 days through PBMCs activated as described previously (Gordon et al., 1999).

Infectivity and inhibition assays in tissue explants
The infectivity of virus preparations was estimated in TZM-bl cells (by luciferase quantitation of cell lysates, Promega, Madison, WI) and PBMCs for HIV-1 isolates or C8166 cells for SIV clones (by measurement of p24 or p27 antigen content in cell culture supernatant, respectively). The extent of luciferase expression was recorded in relative light units (r.l.u) as described previously (Herrera et al., 2009). Viral p24 content in supernatant was measured with HIV-1 p24 ELISA (Zeptometrix Corporation, Buffalo, NY) and p27 with SIV p27 ELISA (Zeptometrix Corporation) following manufacturer’s instructions. Viral growth was reported as pg/ml of p24/p27, extrapolated from the p24/p27 kit-supplied standard curve generated by ODs using a sigmoidal dose-response (Prism, GraphPad). Appropriate dilutions of culture supernatants were applied to ensure data was within the 95% interval of the standard OD range.

Inhibition assays were performed using a standardized amount of virus culture supernatant normalized for infectivity. HEC gels containing TFV, MVC or the combination TFV-MVC were prepared and used at a concentration above the IC50 (TFV 70 μM and/or MVC 3.8 μM) and at one below the IC50 (TFV 7 μM and/or MVC...
0.38 μM). Gels of high and low % were diluted in PBS to the desired high and low concentrations for each drug, respectively. Tissue explants were incubated with drug for 1 h before virus was added for 2 h at 10⁶ TCID₅₀/ml. Explants were then washed four times with PBS to remove unbound virus and drug. Cervicovaginal explants were then transferred to fresh microtiter plates and colorectal explants were transferred onto gelfoam rafts (Welbeck Pharmaceuticals, UK). Tissue explants were cultured in the absence of drug for 15 days and maintained by harvesting approximately two-thirds of culture supernatant at days 3, 7, 11 and 15, and refeeding the cultures with fresh medium. The extent of virus replication in tissue explants was determined by measuring the p24 antigen concentration for HIV-1 and p27 for SIV and RT-SHIV, in supernatants at each harvest time point (HIV-1 p24 ELISA and SIV p27 ELISA, Zeptometrix Corporation). The lower limit of quantification (LLOQ) of the assay was 1.95 pg of p24 or 15.62 pg of p27/ml. The inhibitory potency of the drugs at each concentration was measured at day 15 and, having tested only two concentrations in this pilot study, we estimated the IC₅₀ with a linear regression. The percentage of inhibition by the drugs was normalized relative to p24/p27 values obtained for explants not exposed to virus or compound (0% infectivity) and for explants infected with virus in the absence of drug (100% infectivity).

**Drug concentrations in tissue explants**

To measure drug concentrations during the 15 days of culture of the tissue explants, infectivity assays were set up in replicates to define a baseline of drug level (t₀) (after 3 h of dosing/viral challenge and PBS wash to remove unbound drug and virus) and for each time point of culture supernatant harvest (days 3, 7, 11 and 15). Due to the limited size of the macaque ecto-cervical and vaginal specimens, sparse sampling was performed including explant harvesting at t₀ and day 15. Extracellular tissue concentrations of TFV and MVC and intracellular for TFV-DP were measured (Veselinovic et al., 2014) and converted to ng/mg for TFV and MVC and to fmol/mg for TFV-DP.

Drug concentrations were measured in all matrices using LC-MS/MS methods with ± 15% (20% at the lower limit of quantification (LLOQ)) precision and accuracy. Frozen tissue biopsies were weighed then homogenized in Precellys® hard tissue grinding kit tubes (Cayman Chemical, MI, USA) with cold 70:30 acetonitrile / 1 mM ammonium phosphate buffer (pH 7.4). Following protein precipitation extraction with labeled internal standards (¹³C TFV, ¹³C TFVdp and maraviroc-d₃). For quantification of TFV and TFVdp, TFV was eluted from a Waters Atlantis T3 (100 x 2.1 mm², 3 μm particle size) analytical column, and TFVdp was eluted from a Thermo Biobasic AX (50 x 2.1 mm², 5 μm particle size) analytical column. An API-5000 triple quadrupole mass spectrometer was used to detect all analytes. Data were collected using AB Sciex Analyst Chromatography Software. The dynamic range of this assay was 0.02–20 ng/mL of homogenate for TFV and TFVdp using a 1/concentration weighted linear regression. To convert volume to mass, tissue density was assumed to be 1.06 g/cm³. Concentrations that were detectable but below the limit of quantification (LLOQ) were used.Measurement of MVC, the resulting protein extract was analyzed on a Shimadzu Prominence HPLC by reverse phase chromatography with a Phenomenex Synergi Polar-RP column (50x2mm, 2.5 μm particle size). Detection of the analyte and internal standard used electrospray ionization in the positive mode on an AB Sciex API-5000 triple quadrupole mass spectrometer. The dynamic range of the MVC assay was 0.600–1500 ng/mL of tissue homogenate. All methods were validated as mandated by the industry guidance set by the US DHHS et al., 2001.

**Pharmacological data analysis**

PK and PD parameters were estimated using the tissue-associated drug levels at different time points of explant culture. Concentrations that were detectable but below the limit of quantification were imputed as 50% of the lower limit of quantification (LLOQ) for the analyte and matrix. Concentrations that were below the limit of detection were considered as “0”. Measurement of extracellular concentrations of TFV and MVC and of intracellular concentrations of the diphosphorylated active form of TFV (TFVdp), allowed calculation of PK parameters including, the area under the curve (AUC) between 3 h and day 15 (AUC₃h-15d). and the peak or highest concentration (Cₘₐₓ). For TFV and MVC, Cₘₐₓ was observed at t₀. However, taking into account that TFVdp is a sub-product of TFV which is diphosphorylated in the cellular cytoplasm, TFVdp was not detectable at t₀; instead, Cₘₐₓ was calculated at the second point of our harvesting schedule, day 3. The Cₘₐₓ was estimated directly from experimental data. The AUC₃h-15d after dose was estimated using the log-linear trapezoidal method (Prism, GraphPad). To quantify the pharmacodynamic interaction between TFV and MVC, a previously published non-competitive joint inhibition model (Chakraborty and Jusko, 2002) of the following form was fit to estimate the potency factor Ψ, which is an empirical interaction term, where Ψ = 1 demonstrates additive effects, Ψ < 1 is synergism and Ψ > 1
antagonism (Equation 2). C is the observed tissue concentration of TFV or MVC, E is the AUC_{3-15} of p24 or p27, and by fixing the 50% effective concentration (EC_{50}) and Hill slope (H) parameters from Equation 1.

\[
E = E_0 + \frac{C^{\text{TFV}} \times E_{\text{TFV}}^{\text{MAX}}}{C^{\text{TFV}} + EC^{\text{TFV}}_{50}} \quad \text{(Equation 1)}
\]

\[
E = \left( \frac{C^{\text{TFV}} \times EC^{\text{TFV}}_{50}}{C^{\text{TFV}} + EC^{\text{TFV}}_{50}} \right)^{H_{\text{TFV}}} + \left( \frac{C^{\text{MVC}} \times EC^{\text{MVC}}_{50}}{C^{\text{MVC}} + EC^{\text{MVC}}_{50}} \right)^{H_{\text{MVC}}} \times \left( \frac{C^{\text{TFV}} \times EC^{\text{TFV}}_{50}}{C^{\text{TFV}} + EC^{\text{TFV}}_{50}} \right)^{H_{\text{TFV}}} \quad \text{(Equation 2)}
\]

The p24 or p27 AUC between days 3 and 15 of culture (p24/p27 AUC_{3-15}) were estimated with the non-cumulative viral antigen concentrations at the different time points of supernatant harvest between days 3 and 15 and using the log-linear trapezoidal method (Prism, GraphPad).

**Statistics**

Drug concentrations were log_{10} transformed and correlated with the corresponding log transformed p24 level at day 15 of tissue explant culture post-infection for each animal or subject using a Pearson correlation test. P values were determined using a two-tailed unpaired Student t test, and P < 0.05 was considered statistically significant. TFV measures from cervical, vaginal and colorectal tissues were log_{10} transformed and paired with the corresponding explant infectibility result (i.e. log_{10} p24 or p27) for each sample. Paired TFV and p24 or p27 endpoints were entered into a three parameter, log-log, Hill slope, non-linear model (Equation 3) where the fit of the model was tested by nonlinear least-squares ANOVA and the proportion of variance that each model explained (r^2) was calculated (i.e. 1 - the sum of the squared distances from each fitted curved divided by the squared distances from a horizontal line).

\[
\log_{10}(p24 / p27) = b + (a - b) / 1 + 10^{[(\log_{10}\text{Dose}) - c]} \quad \text{(Equation 3)}
\]

The fit of each three-parameter non-linear model was compared to an alternative four parameter model using the information criterion of Akaike (AIC), where a lower AIC indicates improved model fit (Glatting et al., 2007).

**Study approval**

All animal studies were approved by the Tulane National Primate Research Center (TNPRC) Institutional Animal Care and Use Committee (IACUC). TNPRC is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC no. 000594). The TNPRC Office of Laboratory Animal Welfare (OLAW) assurance number is A4499-01 and U.S. Department of Agriculture registration number is 72-R-0002. All human tissues were collected after receiving signed informed consent from all patients and under protocols approved by the Local Research Ethics Committee.